Is acute myeloid leukemia a liquid tumor?

Maro Ohanian, Stefan Faderl, Farhad Ravandi, Naveen Pemmaraju, Guillermo Garcia-Manero, Jorge Cortes, Zeev Estrov

Research output: Contribution to journalReview article

Abstract

Extramedullary manifestations of acute myeloid leukemia (AML) were described as early as the 19th century. However, the incidence, clinical significance and pathobiology of extramedullary AML remain ill defined. We reviewed case reports, retrospective case series, pilot studies and imaging studies of extramedullary leukemia (EML) to determine its frequency, characteristics, clinical presentation and significance. EML precedes or accompanies development of AML and occurs during or following treatment, even during remission. Although imaging studies are rarely conducted and the true incidence of EML has yet to be verified, authors have reported several estimates based on retrospective and autopsy studies. The incidence of EML in patients with AML of all ages is estimated to be about 9% and EML in children with AML was detected in 40% of patients at diagnosis. The combination of positron emission tomography and computed tomography were the most sensitive and reliable techniques of detecting and monitoring EML. Based on our literature review, the frequency of EML is likely underreported. The well-documented nature of EML in patients with AML suggests that AML can manifest as a solid tumor. The extent to which EML accompanies AML and whether EML is derived from bone marrow are unknown. Furthermore, questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse. Therefore, prospective studies of detection and characterization of EML in patients with AML are warranted.

Original languageEnglish (US)
Pages (from-to)534-543
Number of pages10
JournalInternational Journal of Cancer
Volume133
Issue number3
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Leukemia
Neoplasms
Residual Neoplasm
Incidence
Autopsy
Retrospective Studies
Bone Marrow
Prospective Studies
Recurrence
Survival

Keywords

  • acute myeloid leukemia (AML)
  • chronic myeloid leukemia (CML)
  • extramedullary leukemia (EML)
  • myelodysplastic syndromes (MDS)
  • myeloproliferative neoplasms (MPN)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ohanian, M., Faderl, S., Ravandi, F., Pemmaraju, N., Garcia-Manero, G., Cortes, J., & Estrov, Z. (2013). Is acute myeloid leukemia a liquid tumor? International Journal of Cancer, 133(3), 534-543. https://doi.org/10.1002/ijc.28012

Is acute myeloid leukemia a liquid tumor? / Ohanian, Maro; Faderl, Stefan; Ravandi, Farhad; Pemmaraju, Naveen; Garcia-Manero, Guillermo; Cortes, Jorge; Estrov, Zeev.

In: International Journal of Cancer, Vol. 133, No. 3, 01.08.2013, p. 534-543.

Research output: Contribution to journalReview article

Ohanian, M, Faderl, S, Ravandi, F, Pemmaraju, N, Garcia-Manero, G, Cortes, J & Estrov, Z 2013, 'Is acute myeloid leukemia a liquid tumor?', International Journal of Cancer, vol. 133, no. 3, pp. 534-543. https://doi.org/10.1002/ijc.28012
Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J et al. Is acute myeloid leukemia a liquid tumor? International Journal of Cancer. 2013 Aug 1;133(3):534-543. https://doi.org/10.1002/ijc.28012
Ohanian, Maro ; Faderl, Stefan ; Ravandi, Farhad ; Pemmaraju, Naveen ; Garcia-Manero, Guillermo ; Cortes, Jorge ; Estrov, Zeev. / Is acute myeloid leukemia a liquid tumor?. In: International Journal of Cancer. 2013 ; Vol. 133, No. 3. pp. 534-543.
@article{43cab7d01e684ad78b5aae93756d7771,
title = "Is acute myeloid leukemia a liquid tumor?",
abstract = "Extramedullary manifestations of acute myeloid leukemia (AML) were described as early as the 19th century. However, the incidence, clinical significance and pathobiology of extramedullary AML remain ill defined. We reviewed case reports, retrospective case series, pilot studies and imaging studies of extramedullary leukemia (EML) to determine its frequency, characteristics, clinical presentation and significance. EML precedes or accompanies development of AML and occurs during or following treatment, even during remission. Although imaging studies are rarely conducted and the true incidence of EML has yet to be verified, authors have reported several estimates based on retrospective and autopsy studies. The incidence of EML in patients with AML of all ages is estimated to be about 9{\%} and EML in children with AML was detected in 40{\%} of patients at diagnosis. The combination of positron emission tomography and computed tomography were the most sensitive and reliable techniques of detecting and monitoring EML. Based on our literature review, the frequency of EML is likely underreported. The well-documented nature of EML in patients with AML suggests that AML can manifest as a solid tumor. The extent to which EML accompanies AML and whether EML is derived from bone marrow are unknown. Furthermore, questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse. Therefore, prospective studies of detection and characterization of EML in patients with AML are warranted.",
keywords = "acute myeloid leukemia (AML), chronic myeloid leukemia (CML), extramedullary leukemia (EML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)",
author = "Maro Ohanian and Stefan Faderl and Farhad Ravandi and Naveen Pemmaraju and Guillermo Garcia-Manero and Jorge Cortes and Zeev Estrov",
year = "2013",
month = "8",
day = "1",
doi = "10.1002/ijc.28012",
language = "English (US)",
volume = "133",
pages = "534--543",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Is acute myeloid leukemia a liquid tumor?

AU - Ohanian, Maro

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Pemmaraju, Naveen

AU - Garcia-Manero, Guillermo

AU - Cortes, Jorge

AU - Estrov, Zeev

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Extramedullary manifestations of acute myeloid leukemia (AML) were described as early as the 19th century. However, the incidence, clinical significance and pathobiology of extramedullary AML remain ill defined. We reviewed case reports, retrospective case series, pilot studies and imaging studies of extramedullary leukemia (EML) to determine its frequency, characteristics, clinical presentation and significance. EML precedes or accompanies development of AML and occurs during or following treatment, even during remission. Although imaging studies are rarely conducted and the true incidence of EML has yet to be verified, authors have reported several estimates based on retrospective and autopsy studies. The incidence of EML in patients with AML of all ages is estimated to be about 9% and EML in children with AML was detected in 40% of patients at diagnosis. The combination of positron emission tomography and computed tomography were the most sensitive and reliable techniques of detecting and monitoring EML. Based on our literature review, the frequency of EML is likely underreported. The well-documented nature of EML in patients with AML suggests that AML can manifest as a solid tumor. The extent to which EML accompanies AML and whether EML is derived from bone marrow are unknown. Furthermore, questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse. Therefore, prospective studies of detection and characterization of EML in patients with AML are warranted.

AB - Extramedullary manifestations of acute myeloid leukemia (AML) were described as early as the 19th century. However, the incidence, clinical significance and pathobiology of extramedullary AML remain ill defined. We reviewed case reports, retrospective case series, pilot studies and imaging studies of extramedullary leukemia (EML) to determine its frequency, characteristics, clinical presentation and significance. EML precedes or accompanies development of AML and occurs during or following treatment, even during remission. Although imaging studies are rarely conducted and the true incidence of EML has yet to be verified, authors have reported several estimates based on retrospective and autopsy studies. The incidence of EML in patients with AML of all ages is estimated to be about 9% and EML in children with AML was detected in 40% of patients at diagnosis. The combination of positron emission tomography and computed tomography were the most sensitive and reliable techniques of detecting and monitoring EML. Based on our literature review, the frequency of EML is likely underreported. The well-documented nature of EML in patients with AML suggests that AML can manifest as a solid tumor. The extent to which EML accompanies AML and whether EML is derived from bone marrow are unknown. Furthermore, questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse. Therefore, prospective studies of detection and characterization of EML in patients with AML are warranted.

KW - acute myeloid leukemia (AML)

KW - chronic myeloid leukemia (CML)

KW - extramedullary leukemia (EML)

KW - myelodysplastic syndromes (MDS)

KW - myeloproliferative neoplasms (MPN)

UR - http://www.scopus.com/inward/record.url?scp=84878018504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878018504&partnerID=8YFLogxK

U2 - 10.1002/ijc.28012

DO - 10.1002/ijc.28012

M3 - Review article

C2 - 23280377

AN - SCOPUS:84878018504

VL - 133

SP - 534

EP - 543

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -